Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations ...
It targets CD19 positive B cells and CD70 positive activated T cells, both of which contribute to autoimmune disease. Our Dagger technology is designed to endow the cells with a kind of built-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results